

PRESS RELEASE
18 May 2022 16:15:00 CEST



Regional politicians want TUMT to be introduced as a treatment method for benign prostate enlargement in Halland.

Stina Isaksson and Carita Boulwén, regional board members (SD) in Region Halland, want TUMT to be introduced as a treatment method in the region.

TUMT, transurethral microwave thermotherapy, is the medical term for ProstaLund's treatment of benign prostate enlargement, CoreTherm®. Region Halland is one of the few regions in Sweden where the method is currently not performed.

Isaksson and Boulwén argue for the introduction of TUMT in Halland and point out, among other things, that neither operating rooms, surgical staff nor hospital beds are needed, as in surgery. Furthermore, they point to the potential savings that the region can make, SEK 3.3 million, if CoreTherm® replaces surgery (TUR-P). "We can treat more patients in our region, without long waiting and journey. More patients will be able to get a cure and it will lead to shorter queues."

They continue: "There would be an opportunity to offer more patients a treatment for their age-enlarged prostate in Region Halland, while at the same time reducing costs and freeing up hospital resources within the strained urological operations by using TUMT besides TURP."

The regional board in Halland decided to give the regional office in Halland to prepare the case.

CEO Johan Wennerholm comments: "It is fantastic that even more politicians are paying attention to the obvious gains that CoreTherm® can contribute to in the healthcare system. With a helicopter perspective, the direct savings as such for the treatment are seen and at the same time what the freed-up resources may lead to, here in the form of more treated patients, shorter queues and hospital resources that can be used for other patient groups. It will be very interesting to hear what conclusions the regional office in Halland comes to. Regardless, we are ready to supply equipment and train personnel!"

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com



PRESS RELEASE
18 May 2022 16:15:00 CEST

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB

Phone: +46 40 200 250

E-mail: ca@vhcorp.se

Attachments

Regional politicians want TUMT to be introduced as a treatment method for benign prostate enlargement in Halland.